Different relevance of inactivation and F468 residue in the mechanisms of hEag1 
channel blockage by astemizole, imipramine and dofetilide

Gomez-Varela, D.; Contreras-Jurado, C.; Furini, S.; Garcia-Ferreiro, R.; Stuhmer, W.; Pardo, L. A.

doi:10.1016/j.febslet.2006.08.030

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Different relevance of inactivation and F468 residue in the mechanisms of hEag1 channel blockage by astemizole, imipramine and dofetilide

MPS-Authors

Gomez-Varela, D.
Max Planck Society;

Contreras-Jurado, C.
Max Planck Society;

Furini, S.
Max Planck Society;

Garcia-Ferreiro, R.
Max Planck Society;

Stuhmer, W.
Max Planck Society;

Pardo, L. A.
Max Planck Society;

External Resource

https://www.ncbi.nlm.nih.gov/pubmed/16949586
(Any fulltext)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Gomez-Varela, D., Contreras-Jurado, C., Furini, S., Garcia-Ferreiro, R., Stuhmer, W., & Pardo, L. A. (2006). Different relevance of inactivation and F468 residue in the mechanisms of hEag1 channel blockage by astemizole, imipramine and dofetilide. FEBS Lett, 580(21), 5059-66. doi:10.1016/j.febslet.2006.08.030.

Cite as: https://hdl.handle.net/21.11116/0000-0009-F221-0

Abstract

The relevance of a point mutation at the C-terminal end of the S6 helix (F468) and the introduction of C-type inactivation in the blockage of hEag1 channels by astemizole, imipramine and dofetilide was tested. C-type inactivation decreased block by astemizole and dofetilide but not imipramine, suggesting different binding sites in the channel. F468C mutation increased IC(50) for astemizole and imipramine but in contrast to HERG channels, only slightly for dofetilide. Together with measurements on recovery of blocking, our observations indicate that the mechanism of hEag1 blockage by each of these drugs is different, and suggest relevant structural differences between hEag1 and HERG channels.